In this study, we quantify the expression of PCA3 in a large (n=12,076) localized prostate cancer cohort and relate these data to clinicopathological parameters, generating, to our knowledge, the largest study that correlates PCA3 expression to prostate cancer clinical outcome. This evidence concerns the gene PCA3 and prostate carcinoma.